Protara Therapeutics (TARA) Operating Leases (2019 - 2026)
Protara Therapeutics (TARA) posted quarterly Operating Leases of $1.8 million for Q1 2026, down 41.35% year-over-year from $3.1 million in Q1 2025, and down 15.3% quarter-over-quarter from $2.1 million in Q4 2025.
Protara Therapeutics (TARA) Operating Leases (2019 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Operating Leases for 8 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 41.35% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 41.35% YoY), while the FY2025 annual figure was $2.1 million, down 36.98% from the prior year.
- Operating Leases declined to $1.8 million in Q1 2026 per TARA's latest filing, from $2.1 million in the prior quarter.
- Across five years, Operating Leases topped out at $6.2 million in Q1 2022 and bottomed at $1.8 million in Q1 2026.
- Historically, Operating Leases has averaged $4.4 million across 5 years, with a median of $4.5 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Leases surged 477.86% — and 2026, when it sank 41.35%.
- Protara Therapeutics' Operating Leases stood at $5.5 million in 2022, then dropped by 17.98% to $4.5 million in 2023, then declined by 25.09% to $3.4 million in 2024, then plunged by 36.98% to $2.1 million in 2025, then dropped by 15.3% to $1.8 million in 2026.
- Business Quant data shows TARA's Operating Leases at $1.8 million in Q1 2026, $2.1 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.75 Mn |
| Mar 31, 2026 | 1.79 Mn |
| Dec 31, 2025 | 2.12 Mn |
| Sep 30, 2025 | 3.66 Mn |
| Jun 30, 2025 | 3.95 Mn |
| Mar 31, 2025 | 3.06 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.66 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 4.23 Mn |
| Dec 31, 2023 | 4.48 Mn |
| Sep 30, 2023 | 5.70 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Mar 31, 2023 | 5.23 Mn |
| Dec 31, 2022 | 5.47 Mn |
| Sep 30, 2022 | 5.70 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Mar 31, 2022 | 6.16 Mn |
| Dec 31, 2021 | 6.38 Mn |
| Sep 30, 2021 | 6.60 Mn |